Dianthus initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Dianthus (DNTH) with a Buy rating and no price target The firm says DNTH103 is “highly potent” and selectively targets classical pathway while preserving lectin and alternative pathways, offering differentiated safety versus C2/C5 agents. The Phase 1 data support two week dosing and an at-home autoinjector to provide enhanced convenience, the analyst tells investors in a research note. TD cites DNTH103’s validated mechanism of action and “differentiated safety/convenience” in sizable market opportunities for the Buy rating on Dianthus.